Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles.
Journal
Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531
Informations de publication
Date de publication:
10 03 2022
10 03 2022
Historique:
pubmed:
19
2
2022
medline:
7
5
2022
entrez:
18
2
2022
Statut:
ppublish
Résumé
Our first-generation CXCR4 antagonist TIQ15 was rationally modified to improve drug-like properties. Introducing a nitrogen atom into the aromatic portion of the tetrahydroisoquinoline ring led to several heterocyclic variants including the 5,6,7,8-tetrahydro-1,6-naphthyridine series, greatly reducing the inhibition of the CYP 2D6 enzyme. Compound
Identifiants
pubmed: 35179893
doi: 10.1021/acs.jmedchem.1c01564
doi:
Substances chimiques
Heterocyclic Compounds
0
Receptors, CXCR4
0
Cytochrome P-450 CYP2D6
EC 1.14.14.1
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
4058-4084Subventions
Organisme : NIAID NIH HHS
ID : R01 AI128837
Pays : United States